Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
Rathi N. Pillai, MD; Suresh S. Ramalingam, MD; Meena Thayu, MD; Patricia Lorenzini, RN; Diana A. Alvarez Arias, PhD; Christopher Moy, MS; Natalie Hutnick, PhD; Roland Knoblauch, MD · 2021 · JTO Clinical and Research Reports
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that targeting CD38-positive cells with daratumumab may synergistically enhance atezolizumab’s antitumor activity by increasing the effector T-cell activity. Methods: This phase 1b-2 study included a safety run-in (one cycle of daratumumab plus atezolizumab) and randomized phases (daratumumab plus atezolizumab versus atezolizumab alone). The primary objective of the randomized phas
Abstract by Rathi N. Pillai, MD; Suresh S. Ramalingam, MD; Meena Thayu, MD; Patricia Lorenzini, RN; Diana A. Alvarez Arias, PhD; Christopher Moy, MS; Natalie Hutnick, PhD; Roland Knoblauch, MD, JTO Clinical and Research Reports (2021) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Effects of Src on Proliferation and Invasion of Lung Cancer Cells
Negative / Null Result ReportSecretory Function of Kupffer Cells in Liver Cancer After Cryoablation
Negative / Null Result ReportEffect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
Negative / Null Result ReportImpact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
Negative / Null Result ReportImpact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9
Negative / Null Result ReportAnti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: DOAJ · DOI 10.1016/j.jtocrr.2020.100104